7:15 AM ET
8-K
M&A Deal
Eton Pharmaceuticals Signs $10M M&A Deal with Aquestive Therapeutics, Inc.
Eton Pharmaceuticals acquired exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film from Aquestive Therapeutics for an upfront fee of $10 million and up to $47.5 million in milestones. The deal includes a 20-year supply agreement and targets the $450 million annual U.S. seizure rescue market with an anticipated launch in April 2027.
- Value
- $10M
- Counterparty
- Aquestive Therapeutics, Inc.
- Term
- 20 years